Introduction: A Fork in the Big Pharma Road When Novo Nordisk publicly rebuked Hims & Hers for offering compounded GLP-1 medications , it wasnt just a dispute over one drugit was a proxy war for the future of medicine
But what we are seeing is that GLP-1 coverage is getting more accessible for specific conditions sleep apnea, diabetes, extremely high BMI or a combination of these things but for other conditions, coverage is probably going to get more restrictive
We launched Noom GLP-1 Rx to meet the needs of the market in the U.S
Disease activity markers, including polyarthritis, dactylitis, and systemic inflammation, were linked to higher CV event risk, and atherosclerotic plaque burden correlated with PsA severity
Smoking: a leading factor for the death of chronic respiratory diseases derived from global burden of disease study 2019
Both SGLT-2 inhibitors and GLP-1RA should be the preferred treatment for type 2 diabetes and cardiorenal diseases